Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Cancer Immunol Immunother · 2026 · PMC13013894 · PMID 41874648

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significancep = 0.058so close (0.05 < p ≤ 0.1)

When stratified by sex, a numerical difference was observed in males although this did not reach statistical significance (19.2 months vs 27.0 months, HR 1.98, 95%CI 0.97–4.02, p = 0.058), whereas in females, the median OS was significantly lower in UCSD compared to pUC (6.8 months vs 25.6 months, HR 6.73, 95%CI 1.98–50.44, p < 0.001, Fig. 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.